Aronora Biopharmaceuticals is focused on the development of drugs that dissolve blood clots in a procedure termed thrombolysis. Thrombosis is a frequently occurring condition that causes deadly human ailments. Nearly 2 out of 3 people die of complications resulting from blood clots that plug up important vessels, such as arteries and veins. Existing anti-thrombotic drugs that are used against bad clots fail because highly effective doses also block hemostasis, the physiological good clots that form outside of blood vessels and are needed to stop bleeding after injuries. Safer treatment that that could stop bad clots without causing bleeding would save millions of lives every year. The firm's products are intended to be used in difficult-to-treat, severe, rapidly progressing or catastrophic thrombotic blood clotting diseases; including stroke, heart attack, pulmonary embolism, deep vein thrombosis, lung embolisms, diffused coagulation of blood and other severe acute diseases.
